UBS Group Cuts Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $137.00
Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price target reduced by UBS Group from $154.00 to $137.00 in a research report report published on Friday,Benzinga reports. They currently ...
CWEB3d
UBS Trims Neurocrine Price Target to $137, Still Sees Upside Amid Biotech Volatility
UBS maintained a Buy rating on Neurocrine Biosciences (NASDAQ:NBIX) but reduced its price target to $137 from $154, ...
Market Inference3d
Neurocrine Biosciences Appoints Dr. Sanjay Keswani as CMO
Before joining Neurocrine, Dr. Keswani served as the President and Chief Executive Officer of Immunobrain, a clinical-stage ...
Le Lézard4d
Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer
Neurocrine Biosciences, Inc. today announced the appointment of Sanjay Keswani, M.D., to the company's executive management team as Chief Medical Officer (CMO) effective June 2, 2025. Dr. Keswani, an ...
Neurocrine names Dr. Sanjay Keswani as Chief Medical Officer
Biosciences announced the appointment of Sanjay Keswani, M.D., to the company’s executive management team as Chief Medical ...
Neurocrine Biosciences, Inc.: Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer
Accomplished physician-scientist brings more than 20 years of industry leadership experience and broad R&D expertise in multiple therapeutic areas SAN DIEGO, April 4, 2025 /PRNewswire/ ...
Neurocrine price target lowered to $137 from $154 at UBS
UBS analyst Ashwani Verma lowered the firm’s price target on Neurocrine (NBIX) to $137 from $154 and keeps a Buy rating on the shares. The ...